REGiMMUNE raises $8 million in series B financing

New and existing investors include NIF SMBC Ventures, CSK Venture Capital, Japan Asia Investment and Yasuda Enterprise Development.

Proceeds from the financing will be used to advance the company’s lead program, RGI-2001, to human clinical trials for graft versus host disease (GvHD). Preclinical development for GvHD associated with bone marrow transplantation has been completed and an investigation new drug application is expected to be filed in late 2008.

Haru Morita, president and CEO of REGiMMUNE, said: “This financing underscores our ability to make significant progress towards the clinic and eventual product commercialization.”